The Pharmacy Hub
- License footprint
- 1 states: FL
The Edit Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.3/10
Best for: flat per-dose pricing from a brand that names its pharmacy and prescribing practice
7.3
★★★★☆3.7/5
The Edit scores highest on state availability and ease of access.
Semaglutide
$109first month
then $209/mo ongoing
Tirzepatide
$209first month
then $309/mo ongoing
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not disclosed
Coaching
Not disclosed
See plans →See plans at The Edit →
Compare top-rated alternatives ↓No insurance needed · Vetted by our editors
The Edit is a clinician-led telehealth brand from The Edit Health LLC, a Texas management services organization based in Austin. It sells compounded semaglutide and tirzepatide for weight loss alongside NAD+, sermorelin, glutathione and GHK-Cu protocols. Prescribing is handled by an affiliated independent practice, Arora Health & Aesthetics, and prescriptions are dispensed by named partner pharmacy The Pharmacy Hub in Miami. Prices are published openly on every treatment page, there is no card on file to begin, and the site runs in both English and Spanish.
By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
LegitScript VerifiedFlat price at every doseNames its pharmacyFull refund if not approved2-day cold-chain shippingNo membership feeEnglish and Spanish site
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Vetted alternatives to The Edit
7.3/ 10
Verified partnerSunlight
Best for: compounded GLP-1 with unlimited telehealth visits and free shipping
★★★★☆3.7/5
Editorial score · methodology
$88/mosemaglutide
$157/motirzepatide
CompoundedSemaglutideTirzepatideNAD+SermorelinLegitScript Verified
Get StartedRead full Sunlight review →★★★★☆3.7/5
Editorial score · methodology
$219/mosemaglutide
$299/motirzepatide
CompoundedSemaglutideTirzepatideNAD+SermorelinLegitScript Verified
Get StartedRead full MadeMed review →★★★★☆4.2/5
Editorial score · methodology
$99/mosemaglutide
$99/motirzepatide
CompoundedSemaglutideTirzepatideOrforglipron
Get StartedRead full Found review →The Edit at a glance
- Type
- GLP-1 telehealth provider
- Starting price
- $109/mo
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How we scored The Edit
Each dimension is scored algorithmically from The Edit’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
6.9/10At $209/mo, The Edit runs about 23% above the $170 median for GLP-1 providers, and the first month drops to $109. Pricing is flat across doses, so there is no escalation markup as you titrate up.
Effectiveness25%
7.8/10The Edit offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.5/10Online intake and platform experience — app/portal-based, consult included in the price; 7 platform features disclosed.
Trust & Safety15%
7.5/10Core details confirmed by our editors; no FDA warning letters on file; discloses which pharmacy makes its medication.
Accessibility10%
8.0/10The Edit treats patients in all 50 states.
Support10%
5.6/10The Edit provides standard clinician follow-up; no extended coaching or community program is disclosed.
6scored dimensions
607providers compared
100%verified against live provider sites
Value 25%Effectiveness 25%User Experience 15%Trust & Safety 15%Accessibility 10%Support 10%
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this The Edit review
Last checked August 2026- Confirmed current pricing across 2 dose/plan tiers
- Confirmed availability in all 50 states
- Confirmed what the monthly price does and doesn't include
- Verified the compounding pharmacy partner and its accreditation
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
What we checked
- Provider's own pricing page
- $209–$309/mo across 2 dose/plan tiers — checked August 2026
- State pharmacy licensing & LegitScript status
- LegitScript Verified · compounding partner licensed in 1 state
- FDA warning-letter register
- No letter on file for this provider
- Compounding pharmacy partners
- The Pharmacy Hub
What to expect when you sign up with The Edit
We walked The Edit’s public signup flow in August 2026 to document the process — the steps, pricing transparency, and what’s required — before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)
- 1Browse protocols on the public products page, where every price is shown before any account is created
- 2Start a visit and complete a HIPAA-compliant clinical intake, with no charge and no card on file to begin
- 3A licensed provider in your state reviews the intake and issues a prescription only if appropriate
- 4Medication is dispensed by a licensed compounding pharmacy and ships in unmarked, temperature-controlled 2-day packaging
- 5Ongoing care runs through automated refills, secure chat and a six-month clinical re-evaluation
Price shown before you start
- Every treatment price is published on the public products page and on each treatment page, with no gate.
- The site states plainly that getting started is free with no card on file, and that you are not charged if a protocol is not the right fit.
- The $109 and $209 first-order figures are labeled as a limited-time promotion, with the standing rate shown next to them rather than hidden.
- Prepay tiers are disclosed as billed once at the start of the plan, which is clearer than the per-month framing many competitors use.
- The full legal suite is published and dated, including separate cancellation, refund and shipping policies.
GLP-1 medications The Edit offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Peptides The Edit offers
Beyond GLP-1s, The Edit also offers these peptides — tap any for our evidence-based guide.
Pricing
Prices re-verified
Month-to-month, same price at every doseCompounded
$209$109/mo
Save 48% right nowsemaglutide
$109 first order via an automatically applied $100-off promotion, then $209/month. Prepay tiers are billed once upfront: 3 months $575 ($192/mo), 6 months $1,065 ($178/mo).
Month-to-month, same price at every doseCompounded
$309$209/mo
Save 32% right nowtirzepatide
$209 first order, then $309/month standing rate.
Ready to get started?
Plans and promotions change often — check The Edit's current pricing and active discounts before you decide.
The Edit compounding-pharmacy partners
Each partner below is a 503A or 503B pharmacy that The Edit routes prescriptions through.
What we like
- Publishes a real LegitScript seal (ID 51177190) and names both its dispensing pharmacy and its prescribing medical practice.
- Charges the same price at every dose, so titrating up does not raise the monthly cost.
- Nothing is charged to start, with no card on file, and a full refund if a clinician decides treatment is not appropriate.
- Prices are published on every treatment page rather than gated behind intake, in both English and Spanish.
Watch-outs
- The $209/mo standing semaglutide rate sits above the market median; the $109 headline is a first-order promo, not the ongoing price.
- The 3- and 6-month rates are billed once upfront ($575 and $1,065), not as a lower monthly charge.
- Terms claim all 50 states but also say availability is confirmed during consultation and may vary, so coverage is not guaranteed.
- Cancellation ends at the close of the current billing period and part-used periods are not pro-rated or refunded.
Is The Edit worth it?
What The Edit is selling, in one line, is flat per-dose pricing from a brand that names its pharmacy and prescribing practice. New patients start at $109/month for the first month, but the price steps up to $209/month once that window ends — so treat the headline number as an intro offer, not the standing rate. Its flat, all-dose pricing is a genuine plus for anyone worried about cost climbing as they titrate up.
It is LegitScript-certified. It also charges the same price at every dose and names the pharmacy that fills its prescriptions.
How much The Edit actually costs
- Compounded semaglutide starts at $109 the first month, then $209/month after that, if you go that route.
- Compounded tirzepatide starts at $209 the first month, then $309/month after that, at that tier.
For context, the typical ongoing price across the GLP-1 providers we track is around $170/month. The Edit's standing rate sits at the premium end of that range, well above the cheapest options in the category. The first-month discount is a great way to start cheaply. Still, price out the ongoing rate against a flat-rate provider before you commit long term.
For a direct comparison, Oak runs semaglutide and tirzepatide from $200/month — worth pricing against The Edit before you commit.
Medications: what The Edit prescribes
The Edit prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two molecules with the strongest published weight-loss trial outcomes. The medication is compounded at a licensed pharmacy rather than sold as a brand pen, which is what keeps the price down. The trade-off is the one every compounded provider shares: compounded drugs aren't FDA-approved as finished products.
Who The Edit is best for — and who should skip it
A good fit if you…
- want the cheapest possible way to start a GLP-1 and see how you respond before committing.
- live anywhere in the US and want the certainty that your state is already covered.
Look elsewhere if you…
- want the lowest total cost over 6–12 months — a flat-rate provider like Collective will likely beat the ongoing price.
- specifically want an FDA-approved brand-name pen instead of a compounded formulation — that's not what this provider fills.
- need to bill insurance, since like most of this market it's cash-pay with no claims filed on your behalf.
Trust, safety, and medical oversight
The Edit treats patients in all 50 states, and names the pharmacy that fills its prescriptions, and we found no FDA warning letter on file for it. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.
Bottom line
The Edit is one of the easiest ways to start a GLP-1 cheaply — just go in clear-eyed that the $109 intro price steps up to $209/month once the first month is behind you. Use that window to confirm the medication works for you, then re-check the ongoing math before you settle in.
The Bottom Line
The Edit scores highest on state availability and ease of access.
Score: 7.3/10Best for: flat per-dose pricing from a brand that names its pharmacy and prescribing practiceFrom: $109/mo
Ready to start with The Edit?
Starting at $109/month. See current pricing and start your free consultation.
The Edit might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
- If you want brand-name Ozempic, Wegovy, Mounjaro or Zepbound, consider GobyMeds.
- If the lowest possible monthly price is your top priority, consider Collective (from $59/mo).
- If you want built-in coaching and behavior-change support, consider Found.
Frequently Asked Questions
The Edit is a clinician-led telehealth brand from The Edit Health LLC, a Texas management services organization based in Austin. It sells compounded semaglutide and tirzepatide for weight loss alongside NAD+, sermorelin, glutathione and GHK-Cu protocols. Prescribing is handled by an affiliated independent practice, Arora Health & Aesthetics, and prescriptions are dispensed by named partner pharmacy The Pharmacy Hub in Miami. Prices are published openly on every treatment page, there is no card on file to begin, and the site runs in both English and Spanish. We scored it 7.3/10 across our six-dimension editorial framework.
Yes — The Edit is a legitimate telehealth provider. Our editors independently verified its pricing and offering and scored it 7.3/10 across our six-dimension framework. As with any medication, consult a licensed clinician before starting.
The Edit runs $209/month ongoing, with an introductory price of $109/month for the first month. Pricing varies by medication and dose — see the full breakdown in the pricing table above.
The Edit doesn't require a coupon code — new patients currently get $109/mo for the first month (then $209/mo), applied automatically through the link on this page. Third-party "The Edit promo code" sites are typically fake; the real offer is on The Edit's checkout.
The Edit treats patients in all 50 states.
The Edit offers semaglutide (the active drug in Wegovy/Ozempic) and tirzepatide (the active drug in Zepbound/Mounjaro). These are dispensed as compounded formulations.
The Edit dispenses compounded GLP-1s made by a licensed compounding pharmacy — the same active ingredient as the brand drugs at a lower cash price. Compounded drugs are not FDA-approved as finished products; we cover what that means in the review.
The Edit is a cash-pay program — no insurance is required, which is why the monthly price is transparent up front.
The Edit's price includes medication, the clinician consult and shipping. See the "what's included" strip near the top of this review.
You complete an online intake, a licensed clinician reviews whether a GLP-1 is appropriate for you, and — if approved — your medication ships to your door. New patients currently see a $109 first-month price. You can begin the consultation directly on The Edit's site.
We don't find any safety warnings on file (no FDA action). The concerns our review flags are mostly transparency-related: The $209/mo standing semaglutide rate sits above the market median; the $109 headline is a first-order promo, not the ongoing price; The 3- and 6-month rates are billed once upfront ($575 and $1,065), not as a lower monthly charge; Terms claim all 50 states but also say availability is confirmed during consultation and may vary, so coverage is not guaranteed; Cancellation ends at the close of the current billing period and part-used periods are not pro-rated or refunded. None are safety issues, but they're worth weighing before you sign up.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this The Edit review:
Sources & methodology — as of September 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See The Edit's current pricing
Plans start at $109/month. Start your free consultation to check eligibility and today's price.
Not sold on The Edit?
Vetted alternatives